Почему для лечения ревматоидного артрита не применяются рекомендуемые дозы метотрексата: кто виноват и что делать?
Аннотация
Дискуссия посвящена проблеме применения рекомендуемых для лечения ревматоидного артрита доз метотрексата в рандомизированных клинических сравнительных с генно-инженерными биологическими препаратами исследованиях.
Об авторах
Ю. В. Муравьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522 Москва, Каширское шоссе, 34А
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России
Россия
Россия
115522 Москва, Каширское шоссе, 34А
119991 Москва, ул. Трубецкая, 8, стр. 2
кафедра ревматологии Института профессионального образования
Список литературы
1. Duran J, Bockorny M, Dalal D, et al. Methotrexate dosage as a source of bias in biologic trials in rheumatoid arthritis:a systematic review. Ann Rheum Dis. 2016;75:1595-8. doi: 10.1136/annrheumdis-2016-209383
2. Kremer JM. Bias? Not so fast. Ann Rheum Dis. 2016;75(9):1581-2. doi: 10.1136/annrheumdis-2016-209505
3. Visser K, Katchamart W, Loza E, et al. Multinational evidencebased recommendations for the use of methotrexate in rheumatic disorders with a focus onrheumatoid arthritis: integrating systematic literature research and expert opinion of a broad internationalpanel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086-93. doi: 10.1136/ard.2008.094474
4. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54:3095-103. doi: 10.1002/art.22129
5. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy
6. and toxicity of methotrexate in early rheumatoid arthritis are associated with single nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006;54:1087-95. doi: 10.1002/art.21726
7. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oralversus subcutaneous methotrexate in patients with rheumatoid arthritis:drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549-51. doi: 10.1136/annrheumdis-2014-205228
8. Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oralversus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016;75:1003-8. doi: 10.1136/annrheumdis-2014-206504
9. Braun J, Kä stner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73-81. doi: 10.1002/art.23144
10. Islam MS, Haq SA, Islam MN, et al. Comparative efficacy of subcutaneous versus oralmethotrexate in active rheumatoid arthritis. Mymensingh Med J. 2013;22:483-8.
11. Mü ller RB, von Kempis J, Haile SR, et al. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real- world data from the St. Gallen cohort. Semin Arthritis Rheum. 2015;45:28-34. doi: 10.1016/j.semarthrit.2015.02.009
12. Gunn J, Panopolou A, Steuer A. Efficacy and tolerability of subcutaneous methotrexate for inflammatory arthritis: a retrospective observational cohort study [abstract]. Arthritis Rheum. 2014;66:S1079.
13. Kremer JM. Let's re-examine these MTX points once again. Ann Rheum Dis. 2016;75(8):e54. doi: 10.1136/annrheumdis-2016-209834
14. Duran J, Felson DT. Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials. Ann Rheum Dis. 2016;75(8):e53. doi: 10.1136/annrheumdis- 2016-209791
15. Nair SC, Jacobs JW, Bakker MF, et al; Utrecht Arthritis Cohort Study Group. Determining the lowest optimally effective methotrexate dose for individual ra patients using their dose
16. response relation in a tight control treatment approach. PLoS One. 2016 Mar 17;11(3):e0148791. doi: 10.1371/journal.pone.0148791
17. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509. doi: 10.1136/annrheumdis-2013-204573
18. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study – A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. doi: 10.1002/art.21519
19. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43. doi: 10.1002/art.20568
20. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-81. doi: 10.1016/S0140-6736(04)15640-7
21. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi: 10.1136/ard.2010.137703
22. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870-7. doi: 10.1136/ard.2008.101121
23. Gvozdenovic E, Allaart C, van der Heijde D, et al. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open. 2016 Apr 28;2(1):e000221. doi: 10.1136/rmdopen-2015-000221
24. Kay J, Westhovens R. Methotrexate: the gold standard without standardisation. Ann Rheum Dis. 2009 Jul;68(7):1081-2. doi: 10.1136/ard.2008.102822
Для цитирования:
Муравьев Ю.В., Насонов Е.Л. Почему для лечения ревматоидного артрита не применяются рекомендуемые дозы метотрексата: кто виноват и что делать? Научно-практическая ревматология. 2017;55(1):112-114. https://doi.org/10.14412/1995-4484-2017-112-114
For citation:
Muravyev Yu.V., Nasonov E.L. WHY ARE THE RECOMMENDED METHOTREXATE DOSES NOT USED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: WHO IS GUILTY AND WHAT TO DO? Rheumatology Science and Practice. 2017;55(1):112-114. (In Russ.) https://doi.org/10.14412/1995-4484-2017-112-114
Просмотров: 480
Послать статью по эл. почте 
